Search results
Results from the WOW.Com Content Network
Sanofi-Synthélabo was formed in 1999 when Sanofi merged with Synthélabo; at the time of the merger, Sanofi was the second largest pharmaceutical group in France in terms of sales and Synthélabo was the third largest. The merged company was based in Paris, France. [11]: 18–19 [15]
2008: Sanofi Pasteur acquires Acambis plc, a biotech company. 2009: Sanofi Pasteur acquires major stake in Hyderabad-based Shantha Biotechnics. [21] 2020: Sanofi Pasteur and GlaxoSmithKline have said they are starting clinical trials of their coronavirus vaccine. They hope to have the first results of the trial by December and if it is ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Protein Sciences Corporation is a biotech company based in Meriden, Connecticut. The company develops and produces vaccines and biopharmaceuticals for use against influenza and other diseases. In 2017, the company was acquired by Sanofi for $750 million. [1]
(Reuters) - AI-based drug developer Formation Bio said on Wednesday that it has raised $372 million in a late-stage funding round, with a significant participation from French drugmaker Sanofi.
This list is based on the Forbes Global 2000, which ranks the world's 2,000 largest publicly traded companies.The Forbes list takes into account a multitude of factors, including the revenue, net profit, total assets and market value of each company; each factor is given a weighted rank in terms of importance when considering the overall ranking.
It signed an agreement with Sanofi that granted the France-based biotech giant the right to market Novavax's vaccine in most countries worldwide. Sanofi also acquired the permission to use Novavax ...
NEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not facing imminent ...